X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Candesartan belongs to the sartans class of drugs (angiotensin II receptor blockers, ARB) and is one of the most commonly prescribed blood pressure reducers in Germany. In practice, it is primarily used when patients are unable to tolerate ACE inhibitors such as ramipril due to a dry cough — by far the most common reason for a change.But candesartan is more than just an alternative option: It protects the heart, kidneys and vessels as well as ACE inhibitors, but causes significantly fewer side effects. This guide explains the effect, dosage, how to change ramipril correctly and what BRITE user data shows.
See more detail.gif)
This article is for information only and does not replace medical advice. Candesartan is prescription only. Never change the dose or stop the medication on your own initiative.
Candesartan belongs to the group of sartans – angiotensin-II receptor blockers, which are today among the most important blood-pressure medications worldwide. What makes candesartan special: it is one of the few blood-pressure agents used at the same time for high blood pressure, heart failure, and kidney disease – and practically without a dry cough. Candesartan is a so-called prodrug: it is converted into the active form in the gut and only then absorbed by the body.
| Property | Details |
|---|---|
| Active substance | Candesartan (as candesartan cilexetil – prodrug) |
| ATC code | C09CA06 |
| Drug class | Angiotensin-II receptor blocker (ARB / sartan) |
| Available forms | Tablets 2 mg, 4 mg, 8 mg, 16 mg, 32 mg |
| Half-life | approx. 9 hours |
| Onset of action | 2–3 hours, maximum effect after 4–6 weeks |
| Bioavailability | approx. 15% (prodrug, activated in the gut) |
| Intake | 1× daily, independent of meals |
| Prescription only | Yes |
| Special feature | No dry cough (no rise in bradykinin) |
Candesartan and ACE inhibitors such as ramipril have the same goal: to slow the renin–angiotensin–aldosterone system (RAAS), which regulates blood pressure. Angiotensin II is the central player here – a hormone that narrows blood vessels, retains water and salt, and thus raises blood pressure. Both drug classes prevent angiotensin II from exerting its effect – but in fundamentally different ways.
| ACE inhibitor (e.g. ramipril) | Sartan (e.g. candesartan) | |
|---|---|---|
| Point of attack | Blocks the enzyme ACE, which converts angiotensin I into angiotensin II | Blocks the AT1 receptor, at which angiotensin II acts |
| Result | Less angiotensin II is produced | Angiotensin II is still produced but cannot act |
| Bradykinin | Is NOT broken down → rises → dry cough (up to 20%) | Is broken down normally → NO dry cough |
| Angio-oedema risk | Increased (through bradykinin) | Very rare, but possible (intestinal angio-oedema) |
| Protective effect on heart/kidney | Very well documented (HOPE study) | Well documented (CHARM study, DIRECT study) |
This is one of the most common questions from patients – and the answer lies in a single molecule: bradykinin. ACE inhibitors block the enzyme ACE, which normally has two jobs: to convert angiotensin I into angiotensin II and at the same time to break down bradykinin. So when ACE is inhibited, not only does angiotensin II stop rising further – bradykinin also accumulates, because it can no longer be broken down. Bradykinin irritates the cough receptors in the lungs and triggers a dry, persistent cough in 15–20% of patients.
Candesartan acts at a completely different point – directly at the receptor where angiotensin II would dock. The bradykinin system is not touched at all: bradykinin continues to be broken down normally, and the cough reflex is not triggered. This is the decisive pharmacological advantage of candesartan over ramipril – and the reason sartans are the first choice in ACE-inhibitor intolerance.
Candesartan is approved across a broad spectrum of conditions and is dosed differently depending on the indication. One important principle applies to all uses: the maximum blood-pressure reduction only occurs after 4–6 weeks of regular intake. So anyone who notices no improvement after a week should not increase the dose on their own initiative – the doctor decides that.
| Indication | Starting dose | Target dose | Note |
|---|---|---|---|
| High blood pressure | 8 mg 1× daily | 8–32 mg | Maximum effect after 4–6 weeks |
| Heart failure | 4 mg 1× daily | 32 mg (target dose!) | Increase slowly (doubling every 2 weeks) |
| Kidney protection (diabetic nephropathy) | 8 mg | 16–32 mg | Off-label, but increasing evidence |
| Children (6–17 yrs, < 50 kg) | 4 mg | 8 mg | For hypertension |
| Children (6–17 yrs, > 50 kg) | 4–8 mg | 16 mg | For hypertension |
In heart failure, particularly careful dosing-in is necessary. You start with 4 mg daily and double the dose every two weeks – but only if blood pressure, kidney values, and potassium level are stable. The intended target dose is 32 mg daily; not all patients tolerate this dose, and in those cases the highest well-tolerated dose is the goal. The process takes about 6–8 weeks in total and should be done under regular medical supervision. Record all dose steps in your digital medication plan.
The most common situation in which a switch from ramipril to candesartan takes place is a dry cough on ACE-inhibitor therapy. Many patients suffer for months or even years before they or their doctor trace the cough back to the medication. Yet the switch is medically straightforward and well established in practice.
The switch is usually done like this: on the last day, ramipril is taken in the morning for the last time. The next day, candesartan is started at the equivalent dose. There is no overlap phase – ACE inhibitors and sartans must not be combined (more on this in chapter 6). In the first two weeks after the switch, blood pressure should be measured every morning and evening to ensure the new dose works sufficiently. After 2–4 weeks, a laboratory test is recommended: kidney values (creatinine, GFR) and potassium should be within the normal range.
| Ramipril | Candesartan (approx. equivalent) | Other sartans |
|---|---|---|
| 2.5 mg | 8 mg | Valsartan 80 mg / losartan 50 mg |
| 5 mg | 16 mg | Valsartan 160 mg / losartan 100 mg |
| 10 mg | 32 mg | Valsartan 320 mg / losartan 100 mg + HCT |
An important expectation to set for patients: the dry cough does not disappear immediately after the last ramipril. Bradykinin is still broken down by the body for some time – most patients report that the cough disappears completely after 1–4 weeks. In some patients it takes up to 3 months. If the cough persists on candesartan too, another cause (asthma, reflux, other medications) should be investigated.
Candesartan is regarded as one of the best-tolerated blood-pressure medications of all. In clinical studies the rate of side effects on candesartan was barely higher than on placebo – an unusually good profile for a long-term medication. But this does not mean that side effects are impossible. There are some specific risks that every candesartan patient should know.
Candesartan acts on the RAAS and thereby influences potassium excretion via the kidneys. With healthy kidneys this is no problem – the body regulates the potassium level itself. With impaired kidney function, or when taking potassium supplements or potassium-sparing diuretics at the same time, however, too much potassium can build up in the blood (hyperkalaemia). This is dangerous because raised potassium levels can destabilise the heart rhythm. For this reason, regular lab checks – potassium and creatinine every 3–6 months – are a fixed part of candesartan therapy.
Also important: creatinine can rise slightly at the start of candesartan therapy – a rise of up to 20–30% is normal and not a reason to stop. This is because candesartan slightly relaxes the kidney vessels and thereby changes filtration in the short term. Anyone who does not know this is needlessly alarmed at the first blood result.
| Side effect | Frequency | Note |
|---|---|---|
| Dizziness | Common | Especially at the start of therapy. Stand up slowly! |
| Headaches | Common | Improve after 1–2 weeks |
| Hyperkalaemia (raised potassium level) | Occasional | Check potassium! No potassium salt without medical instruction |
| Impaired kidney function | Occasional | Creatinine slightly raised initially – up to 20–30% is normal |
| Low blood pressure (hypotension) | Occasional | Especially at a high dose or with dehydration |
| Respiratory infections (children) | Very common (in children) | Sore throat, runny nose – usually harmless |
| Angio-oedema (intestinal) | Very rare | Sartans can rarely cause intestinal angio-oedema (abdominal pain, diarrhoea). EMA warning 2025 |
| Dry cough | Very rare (<1%) | Much rarer than with ACE inhibitors (15–20%)! |
A new risk that has been more in focus since the EMA warning in 2025: intestinal angio-oedema on sartans. This involves suddenly occurring severe abdominal pain, nausea, and diarrhoea – with no other identifiable cause. This is very rare, but because it can easily be mistaken for a gastrointestinal infection, this possibility should always be considered in candesartan patients with acute abdominal complaints.
Candesartan has a manageable interaction profile – but the few relevant interactions are clinically significant and can in the worst case lead to acute kidney failure. Check all your combinations in the interaction check.
The "triple whammy" is an alarmingly common and at the same time dangerous three-way combination in everyday practice: a sartan (or ACE inhibitor) + a diuretic + an NSAID (such as ibuprofen or diclofenac). Each of these three substances on its own is well manageable for the kidney. But together they hit kidney function from three different directions at once: the sartan relaxes the kidney vessels, the diuretic removes water from the body, and the NSAID reduces blood flow to the kidney. The result can be acute kidney failure – especially in older patients or in heat and dehydration.
The problem: this combination often arises unintentionally. A patient takes candesartan and a diuretic long-term for high blood pressure – and reaches for ibuprofen from the medicine cabinet for back pain or joint pain. Anyone taking candesartan and a diuretic should therefore avoid ibuprofen and other NSAIDs as a matter of principle and switch instead to paracetamol. The brite interaction check detects this combination automatically.
| Substance / medication | Interaction | Recommendation |
|---|---|---|
| Ibuprofen / diclofenac (NSAIDs) | Weaken the blood-pressure reduction + increase the risk of kidney damage (triple whammy!) | Prefer paracetamol. On long-term therapy: monitor kidney values |
| Potassium supplements / potassium salt | Candesartan raises the potassium level → risk of hyperkalaemia | No additional potassium without medical supervision! |
| Spironolactone / eplerenone | Enhances the rise in potassium | Combination possible in HF, but close potassium monitoring |
| ACE inhibitors (ramipril, enalapril) | Dual RAAS blockade: more side effects, no added benefit | Combination contraindicated! |
| Aliskiren | Like ACE inhibitors: dual RAAS blockade | Contraindicated (especially in people with diabetes) |
| Lithium | Candesartan reduces lithium excretion → toxicity | Monitor lithium levels closely |
| Alcohol | Enhances the blood-pressure-lowering effect → dizziness, fainting | Limit alcohol, especially at the start of therapy |
